MNOV Quote, Financials, Valuation and Earnings

iBio has a net margin of -- compared to MediciNova's net margin of -4444.57%. MediciNova's return on equity of -- beat iBio's return on equity of -148.3%.

MediciNova has a consensus price target of --, signalling upside risk potential of 287.6%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that MediciNova has higher upside potential than iBio, analysts believe MediciNova is more attractive than iBio.

MediciNova has a beta of 0.844, which suggesting that the stock is 15.569% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. MediciNova's net income of -$2.9M is higher than iBio's net income of -$4M. Notably, MediciNova's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

Ikena Oncology has a net margin of -- compared to MediciNova's net margin of --. MediciNova's return on equity of -- beat Ikena Oncology's return on equity of --.

MediciNova has a consensus price target of --, signalling upside risk potential of 287.6%. On the other hand Ikena Oncology has an analysts' consensus of -- which suggests that it could grow by 92.31%. Given that MediciNova has higher upside potential than Ikena Oncology, analysts believe MediciNova is more attractive than Ikena Oncology.

MediciNova has a beta of 0.844, which suggesting that the stock is 15.569% less volatile than S&P 500. In comparison Ikena Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ikena Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Ikena Oncology pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Ikena Oncology quarterly revenues of --. MediciNova's net income of -$2.9M is higher than Ikena Oncology's net income of -$10.2M. Notably, MediciNova's price-to-earnings ratio is -- while Ikena Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 8.20x for Ikena Oncology. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to MediciNova's net margin of -49.65%. MediciNova's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MediciNova has a consensus price target of --, signalling upside risk potential of 287.6%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than MediciNova, analysts believe NovaBay Pharmaceuticals is more attractive than MediciNova.

MediciNova has a beta of 0.844, which suggesting that the stock is 15.569% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MediciNova's net income of -$2.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MediciNova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MediciNova's net margin of -2357.27%. MediciNova's return on equity of -- beat Palatin Technologies's return on equity of --.

MediciNova has a consensus price target of --, signalling upside risk potential of 287.6%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than MediciNova, analysts believe Palatin Technologies is more attractive than MediciNova.

MediciNova has a beta of 0.844, which suggesting that the stock is 15.569% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. MediciNova's net income of -$2.9M is higher than Palatin Technologies's net income of -$7.8M. Notably, MediciNova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.